GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

Clinical trial NCT05191784 · UNKNOWN

Trial details

NCT number: NCT05191784
Sponsor: Genexine, Inc.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Glioblastoma

Start date: 2022-01-26
Primary completion: 2024-12-31
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.